BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$84.09 USD
-0.53 (-0.63%)
Updated Aug 2, 2024 01:00 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About Dividend (TTM)
The company's trailing twelve month (TTM) Dividend is the company's annual dividend. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend value alone. Seek attractive annual dividend values, but only on top rated stocks with a solid payment history.
BMRN 84.09 -0.53(-0.63%)
Will BMRN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?
Other News for BMRN
BioMarin Pharmaceutical Larger Than S&P 500 Component Gen Digital
U.S. Food and Drug Administration Approves BioMarin's BRINEURA? (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
BioMarin gets expanded FDA approval for CLN2 therapy Brineura
BioMarin announces FDA approval of sBLA for BRINEURA